Abbvie Inc
NYSE:ABBV
Abbvie Inc
Free Cash Flow
Abbvie Inc
Free Cash Flow Peer Comparison
Competitive Free Cash Flow Analysis
Latest Figures & CAGR of Competitors
Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Abbvie Inc
NYSE:ABBV
|
Free Cash Flow
$22.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
14%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Free Cash Flow
$7.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Free Cash Flow
$7.4B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Free Cash Flow
$3.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Free Cash Flow
$3.7B
|
CAGR 3-Years
22%
|
CAGR 5-Years
15%
|
CAGR 10-Years
24%
|
|
Seagen Inc
NASDAQ:SGEN
|
Free Cash Flow
-$701.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
See Also
What is Abbvie Inc's Free Cash Flow?
Free Cash Flow
22.1B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Free Cash Flow amounts to 22.1B USD.
What is Abbvie Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
14%
Over the last year, the Free Cash Flow growth was -9%. The average annual Free Cash Flow growth rates for Abbvie Inc have been 10% over the past three years , 12% over the past five years , and 14% over the past ten years .